What is rolapitant, and is it covered by a patent?
Rolapitant is an NK1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting. The drug and its use are typically protected by patents that cover aspects such as the active ingredient (composition), specific formulations, and/or methods of use (for example, antiemetic regimens in particular settings).
However, the specific patent(s) that apply to “rolapitant” depend on the country/jurisdiction and the exact product name, because multiple patents can exist for the same drug under different claim scopes (active ingredient vs. formulation vs. method).
Which rolapitant patents matter most (composition vs. method vs. formulation)?
Patent families for an antiemetic like rolapitant commonly fall into different categories:
- Composition-of-matter patents (protect the active pharmaceutical ingredient itself).
- Formulation or dosage-form patents (protect how the drug is made into a usable product, such as tablet or capsule composition details).
- Method-of-use patents (protect treatment approaches, such as dosing schedules or combinations with other antiemetics for specific patients or chemotherapy contexts).
Which one you care about depends on what you’re trying to determine: whether generics can enter, whether a competitor can sell a similar product, or whether a particular use is still protected.
When does a rolapitant patent expire?
Patent expiration dates depend on:
- The priority date of the patent family (and any resulting filing timelines).
- Country-specific term rules and patent adjustments.
- Whether exclusivity extensions apply (for example, regulatory-related extensions in some jurisdictions).
- Whether there are “evergreening” patents covering new formulations or new dosing methods.
Without the exact patent number and jurisdiction, it’s not possible to state a reliable expiration date.
What are rolapitant’s major patent/market exclusivity risks for competitors?
For competitors, the main practical risks are:
- Being unable to launch a generic or biosimilar until relevant claims expire.
- Receiving injunctions or facing litigation if a product falls within claim scope (for example, a formulation that is too close).
- Competing around still-protected method-of-use claims, even if some composition claims have expired (or vice versa), because different patent types can block different products.
Can generics be launched before all patents expire?
Usually, even when one patent expires, other patents in the same family can still block marketing—especially if:
- A method-of-use patent still covers the way the drug is prescribed.
- A formulation patent still covers the specific dosage form or composition.
- A follow-on patent family is still in force in the target jurisdiction.
Whether a generic can launch early depends on which claims a regulatory submission must address and what patents are listed/treated as blocking in that country.
What I need from you to give the exact rolapitant patent answer
To identify the correct “rolapitant patent,” I need at least one of the following:
- The country/jurisdiction (e.g., US, EP, UK, India, Canada, Japan).
- The exact product name (brand name and manufacturer, if known).
- Any patent number(s) you’ve seen (even partial).
- A link to the page or document where you found the question.
If you tell me the jurisdiction (for example, “US rolapitant patent”), I can narrow down to the specific patents and explain what each one covers and when it expires.
Sources
No sources were provided in your message, so I can’t cite specific rolapitant patent documents yet.